Compare EXG & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EXG | HCM |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.3B |
| IPO Year | 2006 | N/A |
| Metric | EXG | HCM |
|---|---|---|
| Price | $9.58 | $11.40 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 439.7K | 30.7K |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | N/A | $15.62 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.25 | $11.10 |
| 52 Week High | $9.78 | $19.50 |
| Indicator | EXG | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 25.05 |
| Support Level | $9.46 | N/A |
| Resistance Level | $9.74 | $15.59 |
| Average True Range (ATR) | 0.12 | 0.35 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 82.65 | 15.76 |
Eaton Vance Tax-Mgd Glbl Div Eq Inc is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary focus of the fund is capital appreciation. It invests in a diversified portfolio of domestic and foreign common stocks, emphasizing dividend-paying stocks. It writes call options on one or more U.S. and foreign indices for a portion of the value of its common stock portfolio to generate current cash flow from the options premium received. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, consumable fuels, and other sectors.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.